A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 60, Issue 3, Pages 390-395
Publisher
Wiley
Online
2012-08-10
DOI
10.1002/pbc.24271
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.
- (2017) M. W. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.
- (2017) S. Attia et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
- (2011) Till Milde et al. ACTA NEUROPATHOLOGICA
- Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
- (2010) P. S. Bachmann et al. BLOOD
- Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
- (2010) Maryam Fouladi et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy
- (2010) G J Leclerc et al. LEUKEMIA
- Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
- (2010) Yoav Messinger et al. PEDIATRIC BLOOD & CANCER
- Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment
- (2009) Z. Lin et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
- (2009) Richard A. Campbell et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models
- (2009) T. M. Pitts et al. MOLECULAR CANCER THERAPEUTICS
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
- (2008) A. A. Argyriou et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
- (2008) Jeffrey M. Skolnik et al. JOURNAL OF CLINICAL ONCOLOGY
- The aggresome pathway as a target for therapy in hematologic malignancies
- (2008) Tiffany Simms-Waldrip et al. MOLECULAR GENETICS AND METABOLISM
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now